Corporate ActionJun 11, 2026, 04:47 PM
Humacyte Prices Public Offering of 47.6M Shares at $1.05/Share
AI Summary
Humacyte, Inc. announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at $1.05 per share. The company also granted underwriters an option to purchase up to an additional 7,142,857 shares. The offering is expected to generate approximately $46.80 million in net proceeds, or $53.85 million if the option is fully exercised, which will be used to fund the commercialization of Symvess, support a Biologics License Application supplement, develop its product pipeline, and for general corporate purposes. The closing is anticipated around June 12, 2026.
Key Highlights
- Humacyte priced an underwritten public offering of 47,619,048 shares of common stock.
- The shares were offered at a price of $1.05 per share.
- The company granted underwriters a 30-day option to purchase an additional 7,142,857 shares.
- Gross proceeds are expected to be $50 million, before deductions.
- Net proceeds are estimated at $46.80 million, or $53.85 million if the option is fully exercised.
- Proceeds will fund Symvess commercialization, BLA supplement filing, pipeline development, and general corporate purposes.
- The offering is expected to close on or about June 12, 2026.
- Barclays Capital Inc., BTIG, LLC, and Titan Partners Group LLC are acting as joint book-running managers.
Price Impact
More from HUMA